A5047563454- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Diverticular Disease and Complications
- Liver Diseases and Immunity
- Health Systems, Economic Evaluations, Quality of Life
- Celiac Disease Research and Management
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders Research
- Pharmaceutical studies and practices
- Colorectal Cancer Screening and Detection
- Pregnancy and Medication Impact
- Anorectal Disease Treatments and Outcomes
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Esophageal and GI Pathology
- Mycobacterium research and diagnosis
- IL-33, ST2, and ILC Pathways
IRCCS Ospedale San Raffaele
2021-2025
Humanitas University
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025
Vita-Salute San Raffaele University
2021-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2021-2025
Western University
2024-2025
University Foundation
2024-2025
IRCCS Humanitas Research Hospital
2015-2024
Inserm
2013-2024
University of Calgary
2020-2024
Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.We conducted two integrated randomized, double-blind, placebo-controlled trials in patients with active disease. In the trial induction therapy, 374 (cohort 1) received (at a dose 300 mg) or placebo intravenously at weeks 0 and 2, 521 2) open-label disease evaluation week 6. maintenance either cohort who had response to 6 were randomly assigned continue receiving every 8...
This paper is the second in a series of three publications relating to European evidence-based consensus on diagnosis and management Crohn's disease concerns active disease, maintenance medically induced remission surgery. The aims methods ECCO Consensus, as well sections classification are covered first [van Assche et al. JCC 2009a]. final covers post-operative recurrence, fistulating paediatric adolescent IBD, pregnancy, psychosomatics, extraintestinal manifestations complementary or...
Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the of tofacitinib and maintenance therapy.
The efficacy of ustekinumab, an antagonist the p40 subunit interleukin-12 and interleukin-23, as induction maintenance therapy in patients with ulcerative colitis is unknown.We evaluated ustekinumab 8-week 44-week moderate-to-severe colitis. A total 961 were randomly assigned to receive intravenous dose (either 130 mg [320 patients] or a weight-range-based that approximated 6 per kilogram body weight [322]) placebo (319). Patients who had response 8 weeks after administration again...
<h3>Objective</h3> Vedolizumab is a gut-selective antibody to α<sub>4</sub>β<sub>7</sub> integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary safety vedolizumab. <h3>Design</h3> Safety data (May 2009–June 2013) from six trials vedolizumab were integrated. Adverse events evaluated in patients who received ≥1 dose or placebo reported as exposure-adjusted incidence rates number experiencing event per 100 person-years (PYs) exposure....
<h3>Background & aims</h3> Inflammatory bowel disease (IBD) is characterised by chronic intestinal inflammation, resulting from dysregulation of the mucosal immune system and compromised epithelial barrier function. The bile salt, nuclear farnesoid X receptor (FXR), was recently implicated in antibacterial defence aim this study to investigate therapeutic potential FXR agonists treatment inflammation complementary vivo vitro models. <h3>Methods</h3> Colitis induced wild-type (WT)...
Abstract This paper is the second in a series of two publications relating to European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on diagnosis management disease [CD] concerns surgical CD as well special situations including perianal extraintestinal manifestations. Diagnostic approaches medical this ECCO Consensus are covered first [Gomollon et al. JCC 2016].
The management of patients with IBD requires evaluation objective tools, both at the time diagnosis and throughout course disease, to determine location, extension, activity severity inflammatory lesions, as well as, potential existence complications. Whereas endoscopy is a well-established uniformly performed diagnostic examination, implementation radiologic techniques for assessment still heterogeneous; variations in technical aspects degrees experience preferences exist across countries...
Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these inflammatory bowel disease lacking.
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure activity at specific point in time. An instrument to cumulative structural damage the bowel, which may predict long-term disability, needed. The aim of this article outline methods develop an that can bowel damage. project being conducted by International Program New Indexes (IPNIC) group. This instrument, called Disease Digestive Damage Score (the Lémann score), should take into...
European Consensus on the Diagnosis and Management of Iron Deficiency Anaemia in Inflammatory Bowel Diseases
VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point study was to assess effects supplementation with patients affected by relapsing ulcerative colitis (UC) who are already under 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.A total 144 consecutive were randomly treated for 8 weeks dose 3,600 billion CFU/day (71 patients) or placebo (73 patients).In all, 65 group and 66 completed study. decrease...
### 8.1 General Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice for most patients ulcerative colitis (UC) requiring colectomy.1 Pouchitis a non-specific inflammation reservoir and common complication IPAA in UC.2–7 Its frequency related to duration follow up, occurring up 50% 10 years after large series from major referral centres.1–9 The cumulative incidence pouchitis an familial adenomatous polyposis much lower, ranging 0 10%.10–12 Reasons higher UC...